Meeting
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Presenter
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02892123
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 299)
DOI
10.1200/JCO.2021.39.3_suppl.299
Abstract #
299
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
Speaker: Shubham Pant, MD, MBBS
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study.
Speaker: Shubham Pant, MD, MBBS
Videos & Slides
2023 ASCO Annual Meeting
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
Speaker: Shubham Pant, MD
Speaker: Panel Discussion